Cue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's Why

Key Points

• Shares of Cue Biopharma gapped down before trading, opening at $11.06 versus the prior close of $16.6260; the stock later last traded at $15.5140 on a volume of 90,443 shares.
• Analyst sentiment is mixed but averages to a Sell rating despite a recent "Buy" from Wall Street Zen; the company reported $0.30 EPS and $21.94M revenue for the quarter but remains unprofitable with a -96.85% net margin, -165.19% ROE, a market cap of $1.55B and a negative P/E of -50.25.
• Cue is a clinical-stage biotechnology firm developing a Cytokine Release & Targeting (CRT) platform to deliver cytokines to antigen-specific T cells, with multiple lead programs in early-stage clinical trials.

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $16.6260, but opened at $11.06. Cue Biopharma shares last traded at $15.5140, with a volume of 90,443 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CUE. Wall Street Zen raised shares of Cue Biopharma to a "buy" rating in a research note on Saturday, April 11th. Weiss Ratings reissued a "sell (e+)" rating on shares of Cue Biopharma in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of "Sell".

Cue Biopharma Stock Down 4.2%

The company's 50 day moving average price is $0.34 and its 200-day moving average price is $0.45. The stock has a market cap of $1.55 billion, a P/E ratio of -50.25 and a beta of 1.57.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported $0.30 earnings per share (EPS) for the quarter. The firm had revenue of $21.94 million during the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%.

Hedge Funds Weigh In On Cue Biopharma

Several large investors have recently modified their holdings of the business. Boothbay Fund Management LLC raised its stake in shares of Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company's stock valued at $215,000 after acquiring an additional 93,333 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock valued at $75,000 after acquiring an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock valued at $135,000 after acquiring an additional 407,568 shares during the last quarter. GC Wealth Management RIA LLC raised its stake in shares of Cue Biopharma by 35.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company's stock valued at $1,415,000 after acquiring an additional 1,200,000 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Cue Biopharma during the third quarter valued at $62,000. Institutional investors own 35.04% of the company's stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.